The association between polyunsaturated fatty acid consumption and the transition to psychosis in ultra-high risk individuals

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 108, Issue , 2016, Pages 30-37

  Pawelczyk T ^a   Trafalska, E ^a   Kotlicka Antczak, M ^a   Pawelczyk A ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

At risk mental state; Diet; Diet survey; Omega 3 fatty acids; Omega 6 fatty acids; Prevention

Indexed keywords

ARACHIDONIC ACID; DIHOMO GAMMA LINOLENIC ACID; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID; UNSATURATED FATTY ACID;

ADOLESCENT; ADULT; AFFECTIVE PSYCHOSIS; ARTICLE; CONTROLLED STUDY; DIETARY REFERENCE INTAKE; DISEASE COURSE; DRUG USE; EDUCATIONAL STATUS; ESSENTIAL FATTY ACID DEFICIENCY; FAMILY HISTORY; FAT INTAKE; FEMALE; FOLLOW UP; FOOD FREQUENCY QUESTIONNAIRE; HIGH RISK POPULATION; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL ASSESSMENT; POLYUNSATURATED FATTY ACID DEFICIENCY; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SMOKING HABIT; SOCIAL AND OCCUPATIONAL FUNCTIONING ASSESSMENT SCALE; SOCIAL ENVIRONMENT; BLOOD; CLASSIFICATION; FEEDING BEHAVIOR; PSYCHOTIC DISORDERS; YOUNG ADULT;

ADOLESCENT; ADULT; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, UNSATURATED; FEEDING BEHAVIOR; FEMALE; HUMANS; MALE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84961932662     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2016.03.010     Document Type: Article

References (76)

1. Gama C.S., Canever L., Panizzutti B., Gubert C., Stertz L., Massuda R., Pedrini M., de Lucena David F., Luca R.D., Fraga D.B., Heylmann A.S., Deroza P.F., Zugno A.I. Effects of omega-3 dietary supplement in prevention of positive, negative and cognitive symptoms: a study in adolescent rats with ketamine-induced model of schizophrenia. Schizophr. Res. 2012, 141(2-3):162-167.
2. Amminger G.P., Schafer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67(2):146-154.
3. Amminger G.P., Schafer M.R., Schlogelhofer M., Klier C.M., McGorry P.D. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nat. Commun. 2015, 6:7934.
4. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 2002, 58(1):1-10.
5. Arvindakshan M., Ghate M., Ranjekar P.K., Evans D.R., Mahadik S.P. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr. Res. 2003, 62(3):195-204.
6. Peet M., Shah S., Selvam K., Ramchand C.N. Polyunsaturated fatty acid levels in red cell membranes of unmedicated schizophrenic patients. World J. Biol. Psychiatry 2004, 5(2):92-99.
7. Reddy R.D., Keshavan M.S., Yao J.K. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr. Bull. 2004, 30(4):901-911.
8. Amminger G.P., Schafer M.R., Klier C.M., Slavik J.-M., Holzer I., Holub M., Goldstone S., Whitford T.J., McGorry P.D., Berk M. Decreased nervonic acid levels in erythrocyte membranes predict psychosis in help-seeking ultra-high-risk individuals. Mol. Psychiatry 2012, 17(12):1150-1152.
9. Rice S.M., Schafer M.R., Klier C., Mossaheb N., Vijayakumar N., Amminger G.P. Erythrocyte polyunsaturated fatty acid levels in young people at ultra-high risk for psychotic disorder and healthy adolescent controls. Psychiatry Res. 2015, 228(1):174-176.
10. Hoen W.P., Lijmer J.G., Duran M., Wanders Ronald J.A., van Beveren Nico J.M., de Haan L. Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res. 2013, 207(1-2):1-12.
11. Horrobin D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr. Res. 1998, 30(3):193-208.
12. Horrocks L.A., Farooqui A.A. Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostaglandins Leukot. Essent. Fat. Acids 2004, 70(4):361-372.
13. Yao J.K., Magan S., Sonel A.F., Gurklis J.A., Sanders R., Reddy R.D. Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia. Prostaglandins Leukot. Essent. Fat. Acids 2004, 71(3):171-176.
14. Bach S.A., de Siqueira, Leticia V., Muller A.P., Oses J.P., Quatrim A., Emanuelli T., Vinade L., Souza D.O., Moreira J.D. Dietary omega-3 deficiency reduces BDNF content and activation NMDA receptor and Fyn in dorsal hippocampus: implications on persistence of long-term memory in rats. Nutr. Neurosci. 2014, 17(4):186-192.
15. Bondi C.O., Taha A.Y., Tock J.L., Totah, Nelson K.B., Cheon Y., Torres G.E., Rapoport S.I., Moghaddam B. Adolescent behavior and dopamine availability are uniquely sensitive to dietary omega-3 fatty acid deficiency. Biol. Psychiatry 2014, 75(1):38-46.
16. Ozyurt B., Sarsilmaz M., Akpolat N., Ozyurt H., Akyol O., Herken H., Kus I. The protective effects of omega-3 fatty acids against MK-801-induced neurotoxicity in prefrontal cortex of rat. Neurochem. Int. 2007, 50(1):196-202.
17. McCreadie R., Macdonald E., Blacklock C., Tilak-Singh D., Wiles D., Halliday J., Paterson J. Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study. Br. Med. J. 1998, 317:784-785.
18. Sygnowska E., Waskiewicz A., Gluszek J., Kwasniewska M., Biela U., Kozakiewicz K., Zdrojewski T., Rywik S. Intake of consumed products by adults in the Polish population. Results of the WOBASZ program. Kardiol. Pol. 2005, 63(6 Suppl. 4):S670-S676.
19. Dipasquale S., Pariante C.M., Dazzan P., Aguglia E., McGuire P., Mondelli V. The dietary pattern of patients with schizophrenia: a systematic review. J. Psychiatr. Res. 2013, 47(2):197-207.
20. Christensen O., Christensen E. Fat consumption and schizophrenia. Acta Psychiatr. Scand. 1988, 78(5):587-591.
21. Peet M. International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices: an ecological analysis. Br. J. Psychiatry 2004, 184:404-408.
22. Pawelczyk T., Trafalska E., Pawelczyk A., Kotlicka-Antczak M. Differences in omega-3 and omega-6 polyunsaturated fatty acid consumption in people at ultra-high risk of psychosis, first-episode schizophrenia, and in healthy controls. Early Interv. Psychiatry 2015.
23. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):S22-S33. quiz 34-57.
24. Kotlicka-Antczak M., Pawelczyk T., Rabe-Jablonska J., Pawelczyk A. PORT (Programme of Recognition and Therapy): the first Polish recognition and treatment programme for patients with an at-risk mental state. Early Interv. Psychiatry 2014.
25. Yung A.R., Yuen H.P., McGorry P.D., Phillips L.J., Kelly D., Dell'Olio M., Francey S.M., Cosgrave E.M., Killackey E., Stanford C., Godfrey K., Buckby J. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust. N. Z. J. Psychiatry 2005, 39(11-12):964-971.
26. Jaracz J., Grzechowiak M., Raczkowiak L., Rataj K., Rybakowski J. Polish version of Comprehensive Assessment of At Risk Mental States (CAARMS) - the description of the method. Psychiatr. Pol. 2012, 46(1):95-107.
27. Morosini P.L., Magliano L., Brambilla L., Ugolini S., Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr. Scand. 2000, 101(4):323-329.
28. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
29. Morrison A.P., French P., Walford L., Lewis S.W., Kilcommons A., Green J., Parker S., Bentall R.P. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br. J. Psychiatry 2004, 185:291-297.
30. Gronowska-Senger A. Zarys oceny zywienia 2013, Wydawnictwo SGGW, Warszawa. 2nd ed.
31. Wadołowska L. Validation of Food Frequency Questionnaire - FFQ: reliability study [article in Polish]. Bromat Chem. Toksykol. 2005, 38(1):27-33.
32. Kowalkowska J., Slowinska M.A., Slowinski D., Dlugosz A., Niedzwiedzka E., Wadolowska L. Comparison of a full food-frequency questionnaire with the three-day unweighted food records in young Polish adult women: implications for dietary assessment. Nutrients 2013, 5(7):2747-2776.
33. Szponar L., Wolnicka K., Rychlik E. Album fotografii produktów i potraw: Album of photographs of food products and dishes 2000, Instytut Zywności i Zywienia, Warszawa.
34. Kunachowicz H. Wartość odzywcza wybranych produktów spozywczych i typowych potraw 2012, Wydawnictwo Lekarskie PZWL, Warszawa. 6th ed.
35. M. Jarosz, Dietary Guidelines for the Polish Population - amendment 2012 [article in Polish], available at 〈〉 (accessed 02.08.14). http://mail.izz.waw.pl/~it/NORMY/NormyZywieniaNowelizacjaIZZ2012.pdf.
36. Takkunen M., Agren J., Kuusisto J., Laakso M., Uusitupa M., Schwab U. Dietary fat in relation to erythrocyte fatty acid composition in men. Lipids 2013, 48(11):1093-1102.
37. Wallin A., Di Giuseppe D., Burgaz A., Hakansson N., Cederholm T., Michaelsson K., Wolk A. Validity of food frequency questionnaire-based estimates of long-term long-chain n-3 polyunsaturated fatty acid intake. Eur. J. Nutr. 2014, 53(2):549-555.
38. Kiecolt-Glaser J.K., Epel E.S., Belury M.A., Andridge R., Lin J., Glaser R., Malarkey W.B., Hwang B.S., Blackburn E. Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: a randomized controlled trial. Brain Behav. Immun. 2013, 28:16-24.
39. Calder P.C. Omega-3 fatty acids and inflammatory processes. Nutrients 2010, 2(3):355-374.
40. Siegel S., Castellan N.J. Nonparametric Statistics for the Behavioral Sciences 1988, McGraw-Hill, New York. 2nd ed.
41. Gaag M., Smit F., Bechdolf A., French P., Linszen D.H., Yung A.R., McGorry P., Cuijpers P. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr. Res. 2013, 149(1-3):56-62.
42. Henderson D.C., Borba C.P., Daley T.B., Boxill R., Nguyen D.D., Culhane M.A., Louie P., Cather C., Eden Evins A., Freudenreich O., Taber S.M., Goff D.C. Dietary intake profile of patients with schizophrenia. Ann. Clin. Psychiatry 2006, 18(2):99-105.
43. Strassnig M., Brar J.S., Ganguli R. Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr. Bull. 2003, 29(2):393-397.
44. Suvisaari J.M., Saarni S.I., Perala J., Suvisaari, Janne V.J., Harkanen T., Lonnqvist J., Reunanen A. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J. Clin. Psychiatry 2007, 68(7):1045-1055.
45. Blouin M., Tremblay A., Jalbert M.-E., Venables H., Bouchard R.-H., Roy M.-A., Almeras N. Adiposity and eating behaviors in patients under second generation antipsychotics. Obes. (Silver Spring) 2008, 16(8):1780-1787.
46. Saarni S.E., Saarni S.I., Fogelholm M., Heliovaara M., Perala J., Suvisaari J., Lonnqvist J. Body composition in psychotic disorders: a general population survey. Psychol. Med. 2009, 39(5):801-810.
47. Ryan M., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 2003, 160(2):284-289.
48. Ryan M., Flanagan S., Kinsella U., Keeling F., Thakore J.H. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci. 2004, 74(16):1999-2008.
49. Samele C., Patel M., Boydell J., Leese M., Wessely S., Murray R. Physical illness and lifestyle risk factors in people with their first presentation of psychosis. Soc. Psychiatry Psychiatr. Epidemiol. 2007, 42(2):117-124.
50. Hepgul N., Pariante C.M., Dipasquale S., DiForti M., Taylor H., Marques T.R., Morgan C., Dazzan P., Murray R.M., Mondelli V. Childhood maltreatment is associated with increased body mass index and increased C-reactive protein levels in first-episode psychosis patients. Psychol. Med. 2012, 42(9):1893-1901.
51. Manzanares N., Monseny R., Ortega L., Montalvo I., Franch J., Gutierrez-Zotes A., Reynolds R.M., Walker B.R., Vilella E., Labad J. Unhealthy lifestyle in early psychoses: the role of life stress and the hypothalamic-pituitary-adrenal axis. Psychoneuroendocrinology 2014, 39:1-10.
52. Walker C.G., West A.L., Browning L.M., Madden J., Gambell J.M., Jebb S.A., Calder P.C. The pattern of fatty acids displaced by EPA and DHA following 12 months supplementation varies between blood cell and plasma fractions. Nutrients 2015, 7(8):6281-6293.
53. Perkins D.O., Jeffries C.D., Addington J., Bearden C.E., Cadenhead K.S., Cannon T.D., Cornblatt B.A., Mathalon D.H., McGlashan T.H., Seidman L.J., Tsuang M.T., Walker E.F., Woods S.W., Heinssen R. Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project. Schizophr. Bull. 2014.
54. Simopoulos A.P. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed. Pharmacother. 2002, 56(8):365-379.
55. Wall R., Ross R.P., Fitzgerald G.F., Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr. Rev. 2010, 68(5):280-289.
56. Schuchardt J.P., Schneider I., Willenberg I., Yang J., Hammock B.D., Hahn A., Schebb N.H. Increase of EPA-derived hydroxy, epoxy and dihydroxy fatty acid levels in human plasma after a single dose of long-chain omega-3 PUFA. Prostaglandins Other Lipid Mediat. 109- 2014, 111:23-31.
57. Simopoulos A.P. The omega-6/omega-3 fatty acid ratio, genetic variation, and cardiovascular disease. Asia Pac. J. Clin. Nutr. 2008, 17(Suppl. 1):S131-S134.
58. Kirkpatrick B., Miller B.J. Inflammation and schizophrenia. Schizophr. Bull. 2013, 39(6):1174-1179.
59. Rao J.S., Kim H.-W., Harry G.J., Rapoport S.I., Reese E.A. Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients. Schizophr. Res. 2013, 147(1):24-31.
60. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70(7):663-671.
61. Stojanovic A., Martorell L., Montalvo I., Ortega L., Monseny R., Vilella E., Labad J. Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms. Psychoneuroendocrinology 2014, 41:23-32.
62. Bitanihirwe Byron K.Y., Woo T.-U.W. Oxidative stress in schizophrenia: an integrated approach. Neurosci. Biobehav. Rev. 2011, 35(3):878-893.
63. Gawryluk J.W., Wang J.-F., Andreazza A.C., Shao L., Young L.T. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int. J. Neuropsychopharmacol. 2011, 14(1):123-130.
64. Do K.Q., Trabesinger A.H., Kirsten-Kruger M., Lauer C.J., Dydak U., Hell D., Holsboer F., Boesiger P., Cuenod M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur. J. Neurosci. 2000, 12(10):3721-3728.
65. Sun G.Y., Xu J., Jensen M.D., Yu S., Wood W.G., Gonzalez F.A., Simonyi A., Sun A.Y., Weisman G.A. Phospholipase A2 in astrocytes: responses to oxidative stress, inflammation, and G protein-coupled receptor agonists. Mol. Neurobiol. 2005, 31(1-3):27-41.
66. Berger G.E., Wood S.J., Wellard R.M., Proffitt T.M., McConchie M., Amminger G.P., Jackson G.D., Velakoulis D., Pantelis C., McGorry P.D. Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Biol. Psychiatry 2008, 33(10):2467-2473.
67. Smesny S., Milleit B., Hipler U.-C., Milleit C., Schafer M.R., Klier C.M., Holub M., Holzer I., Berger G.E., Otto M., Nenadic I., Berk M., McGorry P.D., Sauer H., Amminger G.P. Omega-3 fatty acid supplementation changes intracellular phospholipase A activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis. Mol. Psychiatry 2013.
68. Smesny S., Milleit B., Schaefer M.R., Hipler U.-C., Milleit C., Wiegand C., Hesse J., Klier C.M., Holub M., Holzer I., Berk M., McGorry P.D., Sauer H., Paul Amminger G. Effects of omega-3 PUFA on the vitamin E and glutathione antioxidant defense system in individuals at ultra-high risk of psychosis. Prostaglandins, Leukot., Essent. Fat. Acids 2015.
69. Schmidt S.J., Schultze-Lutter F., Schimmelmann B.G., Maric N.P., Salokangas R.K.R., Riecher-Rossler A., van der Gaag M., Meneghelli A., Nordentoft M., Marshall M., Morrison A., Raballo A., Klosterkotter J., Ruhrmann S. EPA guidance on the early intervention in clinical high risk states of psychoses. Eur. Psychiatry J. Assoc. Eur. Psychiatr. 2015, 30(3):388-404.
70. Woods S.W., Walsh B.C., Hawkins K.A., Miller T.J., Saksa J.R., D'Souza D.C., Pearlson G.D., Javitt D.C., McGlashan T.H., Krystal J.H. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. 2013, 23(8):931-940.
71. Kantrowitz J.T., Woods S.W., Petkova E., Cornblatt B., Corcoran C.M., Chen H., Silipo G., Javitt D.C. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. The Lancet. Psychiatry 2015, 2(5):403-412.
72. Berger G.E., Wood S.J., Ross M., Hamer C.A., Wellard R.M., Pell G., Phillips L., Nelson B., Amminger G.P., Yung A.R., Jackson G., Velakoulis D., Pantelis C., Manji H., McGorry P.D. Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study. Curr. Pharm. Des. 2012, 18(4):570-575.
73. Markulev C., McGorry P.D., Nelson B., Yuen H.P., Schaefer M., Yung A.R., Thompson A., Berger G., Mossaheb N., Schlogelhofer M., Smesny S., de Haan L., Riecher-Rossler A., Nordentoft M., Chen E.Y.H., Verma S., Hickie I., Amminger G.P. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Early Interv. Psychiatry 2015.
74. Willett W.C., Howe G.R., Kushi L.H. Adjustment for total energy intake in epidemiologic studies. Am. J. Clin. Nutr. 1997, 65(4 Suppl):1220S-1228S. discussion 1229S-1231S.
75. Roerig J.L., Mitchell J.E., de Zwaan M., Crosby R.D., Gosnell B.A., Steffen K.J., Wonderlich S.A. A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors. J. Clin. Psychopharmacol. 2005, 25(5):413-418.
76. Case M., Treuer T., Karagianis J., Hoffmann V.P. The potential role of appetite in predicting weight changes during treatment with olanzapine. BMC Psychiatry 2010, 10:72.